MindWalk Holdings (HYFT) Long-Term Deferred Tax (2020 - 2026)

MindWalk Holdings (HYFT) posted quarterly Long-Term Deferred Tax of $698866.8 for Q2 2026, up 4083.78% quarter-over-quarter from $16704.2 in Q4 2021.

Analysis

MindWalk Holdings (HYFT) Long-Term Deferred Tax (2020 - 2026) Analysis & Trends

MindWalk Holdings (HYFT) has reported Long-Term Deferred Tax for 2 consecutive years, with $698866.8 the latest figure, recorded in Q2 2026.

In Q2 2026, Long-Term Deferred Tax changed N/A year-over-year to $698866.8; the TTM figure through Apr 2026 stood at $698866.8 (changed N/A YoY), while the FY2026 annual figure was $698866.8, changed N/A from the prior year.
Long-Term Deferred Tax rose to $698866.8 in Q2 2026 per HYFT's latest filing, from $16704.2 in the prior quarter.
Across five years, Long-Term Deferred Tax topped out at $698866.8 in Q2 2026 and bottomed at $698866.8 in Q2 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.31 Bn	131.46 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.65 Bn	77.66 Bn	3.93 Bn
3	Argenx Se	63.46 Bn	58.27 Bn	1.37 Bn
4	Moderna	57.94 Bn	52.80 Bn	52.00 Mn
5	Revolution Medicines	44.05 Bn	44.05 Bn	-
6	BeOne Medicines	39.96 Bn	34.86 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.16 Bn	31.85 Bn	992.69 Mn
8	Royalty Pharma	28.44 Bn	27.60 Bn	-
9	Insmed	27.32 Bn	26.16 Bn	358.27 Mn
10	MindWalk Holdings	60.76 Mn	52.48 Mn	1.82 Mn

Historic Data

Download Data